SOUTH SAN FRANCISCO, CA, Tenvie Therapeutics launched with a commitment to transform the treatment of neurological diseases.

The company combines a deep and diverse portfolio of small molecule assets, including programs acquired from Denali Therapeutics Inc., with a proven team of research and development leaders. The $200 million in funding led by ARCH Venture Partners, F-Prime Capital, Mubadala Capital, with participation from additional high-quality investors, will accelerate Tenvie's growth into a multi-clinical asset company.